triple negative breast cancer

[Cell Death Discovery] Researchers reported at the first time that JWA gene activating compound 1 (JAC1) inhibited the proliferation of TNBC in vitro and in vivo experimental models.

[Scientific Reports] Researchers analyzed in vitro the effect of lysophosphatidic acid (LPA)18:1 and the LPA receptor 1 (LPAR1), LPAR3, and LPAR2 inhibitor Ki16425 on cellular functions of different human breast cancer cell lines and the human breast epithelial cell line, as well as Interleukin 8, Interleukin 6 and tumor necrosis factor-alpha cytokine secretion after LPA-incubation.

[Cellular Oncology] Scientists investigated signaling cascades of B cell lymphoma 6 (BCL6) in the CSC compartment of triple negative breast cancers, and the mechanisms that govern its activity, mainly through Notch signaling.

[Molecular Cancer Research] Scientists found that cancer-associated fibroblasts predominantly secreted hepatocyte growth factor (HGF) and activated MET receptor tyrosine kinase in TNBC cells.

[McGill Reporter] The 2021 Discovery of the Year went to the work of Jean-Jacques Lebrun and his team to unveil of the genetic mechanisms at work in aggressive TNBC and the discovery of a promising targeted combination therapy.

[Cytometry Part A] Researchers developed a rapid semi-quantitative method for in situ imaging of bacteria and multiplex cell phenotypes on the same solid tumor tissue sections.